oxaliplatin + capecitabine + panitumumab

This is a combination regimen consisting of three drugs: oxaliplatin, capecitabine, and panitumumab. Oxaliplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and inhibits DNA synthesis. Capecitabine is an oral prodrug converted to 5-fluorouracil (5-FU), which inhibits thymidylate synthase and disrupts DNA synthesis in rapidly dividing cells. Panitumumab is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking ligand-induced activation of EGFR signaling pathways involved in cell proliferation and survival. This combination has been studied as first-line therapy for metastatic colorectal cancer, particularly in patients with RAS wild-type tumors[1][3][6]. The regimen leverages the cytotoxic effects of chemotherapy with targeted inhibition of EGFR to improve outcomes in selected patient populations.

Brand names

Vectibix (for panitumumab)Eloxatin (for oxaliplatin)Xeloda (for capecitabine)

Other names

oxaliplatin + capecitabine + panitumumabXELOX plus panitumumabCAPOX plus panitumumab